25 September 2017
Dr. Kathrin Hemmer attended the Translational Medicine 2017 conference in Prague which was organized by EATRIS. The theme of this conference was “Enhancing Predictivity in Medicines Development” and focused on bringing together the latest approaches to increase chances of success in drug development, from novel in vitro systems to new biomarkers or clinical trial methodology for patient selection and stratification.
Kathrin was selected to give a presentation about our human midbrain-specific organoids that serve as a novel approach for advanced in vitro disease modeling and therapy development.
06 September 2017
BTech is proud to announce the official accreditation as private research institution (Agrément pour un organisme de recherche qui relève du secteur privé) by the Luxembourgish Ministry of Economy.
28 August 2017
BTech becomes member of the LRRK2 Consortium organised by The Michael J Fox Foundation. This membership is valid until December 2020. The consortium comprises researchers and drug makers studying and/or therapeutically targeting LRRK2 Within the LRRK2 Consortium, BTech aims to contribute with its proprietary Midbrain organoid technology to ongoing efforts to understand, model, and eventually treat Parkinson’s disease caused by mutations in the gene LRRK2.
7 July 2017
Evotec and BTech collaborate.
Evotec AG in Hamburg/Germany and BTech recently entered a first joint agreement in the field of gene-editing in order to generate cell lines with an application for lysosomal storage disorders. Both parties anticipate that this is just a first step towards a more intense future collaboration. Prof. Dr. Jens Schwamborn CSO of BTech, commented: "I am very happy about this new collaboration. Evotec and BTech have great collaborative approaches and I am looking forward to the future interactions".
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com or follow @EvotecAG on Twitter .
15 June 2017
BTech awarded “Healthcare startup 2017” at Luxembourg Healthcare Summit.
First held in 2014, the Luxembourg Healthcare Summit is a central event for idea exchange and networking for healthcare professionals and researchers in the country and beyond. Over 100 participants joined the event on 15 June 2017 to discuss current issues of P4 medicine, participate in workshops and enjoy the networking opportunities with other local and international experts.
At the award-ceremony, BTech was honored with the Healthcare Startup award for the 3D Brain-on-a-Chip technology.
“We are delighted to be recognized with this prestigious award”, says Prof. Jens Schwamborn, “It shows that our technology is seen as an important step to advance P4 medicine for neurodegenerative diseases.”